TC BioPharm (Holdings) Analyst Ratings
TC BioPharm (Holdings) Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 01/26/2023 | 123.33% | HC Wainwright & Co. | → $9 | Initiates Coverage On | → Buy |
| 03/28/2022 | 24.07% | EF Hutton | → $5 | Initiates Coverage On | → Buy |
| 日期 | 上/下行 | 分析師公司 | 价格目標變更 | 評級變更 | 上一頁/目前評分 |
|---|---|---|---|---|---|
| 01/26/2023 | 123.33% | HC 溫賴特 & 有限公司. | → 9 美元 | 啟動覆蓋範圍 | → 購買 |
| 03/28/2022 | 24.07% | EF 赫頓 | → 5 美元 | 啟動覆蓋範圍 | → 購買 |
What is the target price for TC BioPharm (Holdings) (TCBP)?
天進生物醫藥 (控股) (TCBP) 的目標價格是多少？
The latest price target for TC BioPharm (Holdings) (NASDAQ: TCBP) was reported by HC Wainwright & Co. on January 26, 2023. The analyst firm set a price target for $9.00 expecting TCBP to rise to within 12 months (a possible 123.33% upside). 2 analyst firms have reported ratings in the last year.
中科溫萊特有限公司於 2023 年 1 月 26 日報導了 TC 生物醫藥（控股）（納斯達克股票代碼：TCBP）的最新價格目標。該分析師公司設定了 9.00 美元的價格目標，預計 TCBP 將在 12 個月內上升（可能上漲 123.33％）。2 分析師公司在去年報告了評級。
What is the most recent analyst rating for TC BioPharm (Holdings) (TCBP)?
TC 生物醫藥（控股）（TCBP）的最新分析師評級為何？
The latest analyst rating for TC BioPharm (Holdings) (NASDAQ: TCBP) was provided by HC Wainwright & Co., and TC BioPharm (Holdings) initiated their buy rating.
TC 生物製藥（控股）（納斯達克股份代號：TCBP）的最新分析師評級由 HC 溫賴特公司提供，TC 生物製藥（控股）發起了買入評級。
When is the next analyst rating going to be posted or updated for TC BioPharm (Holdings) (TCBP)?
TC 生物醫藥（控股）（TCBP）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of TC BioPharm (Holdings), and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for TC BioPharm (Holdings) was filed on January 26, 2023 so you should expect the next rating to be made available sometime around January 26, 2024.
分析師在進行了廣泛的研究後獲得股票評級，其中包括通過公共財務報表，與 TC BioCharm（控股）的高管和客戶交談以及聽取盈利電話會議。大多數分析師每三個月這樣做一次，因此您應該每年每家公司獲得 4 個評級。TC 生物製藥（控股）的最後評級於 2023 年 1 月 26 日提交，因此您應該預計下一個評級將在 2024 年 1 月 26 日左右的某個時間提供。
Is the Analyst Rating TC BioPharm (Holdings) (TCBP) correct?
分析師評級 TC 生物製藥（控股）（TCBP）是否正確？
While ratings are subjective and will change, the latest TC BioPharm (Holdings) (TCBP) rating was a initiated with a price target of $0.00 to $9.00. The current price TC BioPharm (Holdings) (TCBP) is trading at is $4.03, which is within the analyst's predicted range.
雖然評級是主觀的並且會發生變化，但最新的 TC 生物製藥（控股）（TCBP）評級是啟動的，目標價格為 0.00 美元至 9.00 美元。TC 生物製藥（控股）（TCBP）的當前價格為 4.03 美元，這是分析師的預測範圍內。